Final Analysis from AVEO Pharmaceuticals' Phase 2 Trial of Tivozanib in ... - PipelineReview.com (press release) PDF Print
PipelineReview.com (press release)
The company's lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.